Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16847816 | 0.87 | F2 (0.52) | F2NTSR1NTSR2LNPEPANPEP | |
| SCHEMBL30512499 | 0.86 | F2 (0.51) | F2NTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL29679828 | 0.85 | F2 (0.52) | F2NTSR1NTSR2LNPEPANPEP | |
| SCHEMBL31243914 | 0.85 | OPRD1 (0.63) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29472195 | 0.85 | F2 (0.52) | F2NTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL30168761 | 0.85 | F2 (0.58) | F2LNPEPANPEP | |
| SCHEMBL30092917 | 0.85 | NPY4R (0.56) | F2NTSR1NTSR2 | |
| SCHEMBL30798736 | 0.85 | F2 (0.53) | F2NTSR1NTSR2LNPEPANPEP | |
| SCHEMBL31243949 | 0.84 | OPRD1 (0.61) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30657434 | 0.84 | NPY1R (0.49) | F2NTSR1NTSR2LNPEPOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | F2 1066/4885NTSR1 2953/4885NTSR2 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.